.jpg)
Gilead stops hepatitis drug test after ‘adverse events’
Tuesday, April 20, 2010
Citing “significant laboratory abnormalities and adverse events” in patients, Gilead Sciences stopped a clinical test of a hepatitis C drug.
The Foster City company (NASDAQ: GILD) will review data from this Phase II test of GS 9450, a caspase inhibitor. The company has been studying it for treatment of hepatitis C and also for nonalcoholic steatohepatitis.
Gilead licensed the drug from LG Life Sciences Inc. in 2007, paying $20 million upfront for the rights to the drug except in Korea, China and India. The company also agreed to pay for a collaborative research program and to pay milestones of up to $182 million if the drug did well in development.
“Patient safety is Gilead’s top priority,” the business said in a press release.
Gilead didn’t describe the problems in detail.
Subscribe to:
Post Comments (Atom)
.JPG)
No comments:
Post a Comment